Thread by @Biff234523 on Thread Reader App
Why Novavax is the better COVID-19 vaccine
Why Novavax is the better COVID-19 vaccine
Novavax
One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trial
Excellent durability up to one year following Novavax booster doses shown in a new study from Japan.
Correlates of protection estimate 66% throughout the first year following first booster, and 88% throughout second year after 2nd booster.
NUVAXOVID™ Vaccine Locator | Patient Site
How to find a Novavax vaccine near you.
📢💉Novavax (Nuvaxovid) availability update for: Wednesday, September 24th, 2025
Novavax (Nuvaxovid) availability update for: Wednesday, September 24th, 2025
Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment - Sep 4, 2025
Novavax COVID-19 vaccine is now approved in Japan for individuals aged 6 and older.
Novavax Availability Update 📢
Novavax banks on vaccine supply partnerships to boost 2025 revenue
Novavax COVID-19 Vaccine Linked to Fewer Adverse Effects in Health Care Workers and First Responders
“Novavax COVID-19 Vaccine Linked to Fewer Adverse Effects in Health Care Workers and First Responders”
Novavax COVID-19 Vaccine Linked to Fewer Adverse Effects in Health Care Workers and First Responders
U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine - May 19, 2025
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial - Jun 11, 2025
FDA Review of Novavax’s COVID-19 Vaccine
Biff #SARSisAirborne 🍉 (@Biff248824) on X
“Yesterday’s FDA VRBPAC meeting was a big success, we got everything that we were hoping for within the scope of the meeting agenda:
- Novavax is permitted to continue using a monovalent JN.1 target (1⬇️), which they showed is still inducing robust neutralizing antibody titers across JN.1 lineage strains, such as predominant LP.8.1 (2⬇️). The mRNA manufacturers are also permitted to target LP.8.1, if they wish…”
Comparative duration of neutralizing responses and protections of COVID-19 vaccination and correlates of protection
Novavax for the win. See stats.
Comparative duration of neutralizing responses and protections of COVID-19 vaccination and correlates of protection
Thread by @michaelzlin on Thread Reader App
More details on Novavax approval. I am not convinced anyone will be able to “self-report” medical condition allowing access if under 65, as author hopes.
FDA Approves Novavax Covid Vaccine With Stricter New Conditions
Novavax access now extremely limited.
Novavax Sales Jump 600% YoY as COVID-19 Vaccine Still in Limbo at FDA
Novavax says talks with FDA on COVID vaccine approval ongoing calming investor fears
Novavax says its COVID-19 shot is on track for full FDA approval after delay
FDA chief says they're looking at whether to approve COVID shots for next winter
“Makary's remarks echo his justification for delaying Novavax's COVID-19 vaccine, which was expected to get full approval on April 1. Novavax said Monday that the FDA had asked the company to commit to another clinical trial of the shot.”
FDA may ask Novavax to conduct additional trials of its Covid-19 vaccine to receive full approval | CNN
I finally got a Novavax booster! However the entire process was *messy*. You bet I will be writing to Novavax. Patients AND pharmacists should have proper knowledge, training, and access! 1/12— Nicole Lee Schroeder, PhD (@Nicole_Lee_Sch) March 14, 2025
“I noted I was there for a Novavax booster, my pharmacist went "oh you mean COVID?" I said yes, the Novavax booster to protect against COVID. He then tried to give me a Pfizer booster. Then admitted Novavax was expired and he had no orders for more. 5/12…”
The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose
New RCT comparing Moderna bivalent and Novavax (original strain) as a fourth dose. Novavax has:
- lower side effects
- similar cell mediated immunity, lower IgG response
- potentially broader protection vs variants
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(24)00245-3/fulltext
A study of 1,196 adolescents in the US found that the Novavax COVID-19 vaccine (NVX-CoV2373) was 73.5% effective at preventing SARS-CoV-2 infection, including asymptomatic cases.
Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST)
“Protein-based COVID vaccine NVX-CoV2373 elicited similar reactogenicity to MenACWY.”
Protein-based COVID vaccine NVX-CoV2373 elicited similar reactogenicity to MenACWY.
New RCT study shows the "conventional" Novavax COVID vaccine has a similar side effect profile to the routine meningococcal vaccine, and fewer side effects than the mRNA options.
“New RCT study shows the ‘conventional’ Novavax COVID vaccine has a similar side effect profile to the routine meningococcal vaccine, and fewer side effects than the mRNA options. Side effects are a leading cause of COVID vaccine hesitancy. This can help.”
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
“Novavax has much lower Ab responses, but equivalent efficacy/protection. This is possibly because NVX trains a proportionally more diverse set of immune factors like Fc effector functions”
Another paper from the PICOBOO randomized trial, evaluating second boosters after mRNA priming.
A trio of Novavax preprints, showing 1) remarkable durability 6 months, 2) cross protection against newer variants, and 3) low reactogenicity (side effects), supporting NVX as an excellent booster platform.
“A trio of Novavax preprints, showing 1) remarkable durability >6 months, 2) cross protection against newer variants, and 3) low reactogenicity (side effects), supporting NVX as an excellent booster platform.”
Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea
Novavax data from South Korea 2022, 2 doses Novavax vs 3 doses of Pfizer.
Novavax - 19,485 infected within 6 months out of 104,004.
Pfizer - 10,445 infected out of 33,841, within 6 months. Severe infection was similar.
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-70 years old.
From a randomized trial, proof that the Novavax booster induces less acute side effects and more sustained levels of anti-spike IgG antibodies than mRNA shots